Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx for Ovarian Failure
NCT05158933Phase 1Withdrawn
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in primary ovarian insufficiency (POI), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Safety (adverse events) at 4 years. Planned start Apr 2025; status: withdrawn.
02
Drugs
AlloRx
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05158933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158933.